Related Experiment Video
Updated: Jul 21, 2026
Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
Published on: November 15, 2024
HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: the benefit of corticosteroids
1Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, Virginia, USA.
Insights
Corticosteroids significantly improve platelet counts and liver function in women with HELLP syndrome. Two doses of betamethasone every 12 hours were most effective for improving liver function.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Pharmacology
Background:
- HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is a severe pregnancy complication.
- Effective management strategies for HELLP syndrome are crucial for maternal and fetal outcomes.
Purpose of the Study:
- To evaluate the efficacy of corticosteroids in treating HELLP syndrome.
- To compare the effects of different corticosteroid regimens on platelet counts and liver function.
Main Methods:
- A study involving 93 pregnant patients diagnosed with HELLP syndrome.
- Administration of intramuscular betamethasone or dexamethasone.
- Comparison of pre- and post-treatment hematologic and liver function parameters.
Main Results:
- Corticosteroid treatment led to a significant increase in platelet counts (23.3 x 10(3)/microL).
- Statistically significant reductions were observed in liver enzymes: ALT (31.6 IU/L), AST (52.1 IU/L), and ALP (7.6 IU/L).
- Betamethasone (12 mg every 12 hours) showed the greatest improvement in liver function.
Conclusions:
- Corticosteroids are effective in improving hematologic abnormalities in HELLP syndrome.
- The most effective regimen involved two doses of betamethasone administered 12 hours apart.
Objective:
The purpose of this study was to determine the effect of corticosteroids on platelet counts and liver functions in women with pregnancies complicated by the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome.
Study Design:
The study group consisted of 93 patients between 24 and 34 weeks' gestation diagnosed with HELLP syndrome. All were given intramuscular injections of either betamethasone or dexamethasone. The 3 most common regimens used were 12 mg of intramuscular betamethasone administered twice 12 hours apart, 12 mg of intramuscular betamethasone administered twice 24 hours apart, and 6 mg of intramuscular dexamethasone administered 4 times 6 hours apart. Precorticosteroid and postcorticosteroid platelet counts and liver function test results were compared. The differences in improvement in hematologic abnormalities among the 3 corticosteroid regimens were also analyzed.
Results:
The hematologic abnormalities seen in the 93 patients with HELLP syndrome improved after the administration of corticosteroids. The platelet count increased by 23.3 x 10(3)/microL (P <.001). A statistically significant decrease was seen in liver enzyme levels. The alanine aminotransferase decreased by 31.6 IU/L, the aspartate aminotransferase decreased by 52.1 IU/L, and the alkaline phosphatase decreased by 7.6 IU/L. Of the 3 regimens used, 2 doses of 12 mg of intramuscular betamethasone given every 12 hours improved the liver function to the greatest degree.
Conclusions:
This study demonstrates that corticosteroids produce a significant improvement in the hematologic abnormalities associated with HELLP syndrome. Two doses of betamethasone given 12 hours apart was the most effective corticosteroid regimen.
Related Concept Videos
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:24Cirrhosis II: Pathophysiology